Skip to main content
Zenas BioPharma, Inc. logo

Zenas BioPharma, Inc. — Investor Relations & Filings

Ticker · ZBIO ISIN · US98937L1052 US Manufacturing
Filings indexed 147 across all filing types
Latest filing 2025-04-28 Annual Report
Country US United States of America
Listing US ZBIO

About Zenas BioPharma, Inc.

https://zenasbio.com/

Zenas BioPharma is a clinical-stage biopharmaceutical company dedicated to the development and commercialization of transformative therapies for autoimmune diseases. The company is advancing a pipeline of immunology-based treatments to address significant unmet patient needs. Its two late-stage franchises are obexelimab and orelabrutinib. Obexelimab is an investigational bifunctional monoclonal antibody designed to suppress B cell activity by co-engaging CD19 and FcγRIIb. Orelabrutinib is an investigational, highly selective, CNS-penetrant oral small molecule BTK inhibitor. Zenas aims to become a global leader in providing innovative treatments for patients with autoimmune conditions.

Recent filings

Filing Released Lang Actions
ARS
Annual Report
2025-04-28 English
DEFA14A
Proxy Solicitation & Information Statement Classification · 100% confidence The document is a Schedule 14A proxy statement filed with the SEC, specifically labeled as a Definitive Additional Materials proxy statement for the Annual Meeting of Zenas BioPharma, Inc. It includes voting instructions, details about director nominees, and ratification of the independent auditor. The content is focused on soliciting shareholder votes and providing information related to the upcoming Annual Meeting. It is not the Annual Report itself, nor is it a report of voting results or a remuneration report. The document fits the definition of Proxy Solicitation & Information Statement (PSI), which includes materials sent to shareholders to provide information and request votes for meetings.
2025-04-28 English
DEF 14A
Proxy Solicitation & Information Statement
2025-04-28 English
OWNERSHIP DOCUMENT
Director's Dealing
2025-04-17 English
Major Shareholding Notification 2025
Major Shareholding Notification
2025-04-02 English
OWNERSHIP DOCUMENT
Director's Dealing
2025-03-21 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.